Press Release

« Back
Apr 01, 2015

Semler Launches WellChec™ Platform

PORTLAND, Ore., April 1, 2015 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), an emerging medical risk assessment company that develops, manufactures and markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases, today announced the launch of its multi-test platform, WellChec™, to perform risk assessments for the healthcare insurance industry.

The catalyst for preventative medicine is to recognize disease processes early in their course and to institute care management to affect clinical outcomes. However the primary care physician shortage impedes efforts to make these early diagnoses and interventions. Cost effective wellness is desired by patients, the government, physicians and the insurance industry. Now, Semler's suite of services called WellChec™ is available to do basic tests for diseases of the arteries, lungs, eyes, nerves and heart.

"We believe the economy of scale to combine tests and services provides greater return on investment for our clients, enhanced revenue opportunity for us and may reduce overall healthcare expenditures for disease management. It is the intent of the service to both provide the equipment and tools to do the tests as well as personnel on a sub-contracted basis to perform the measurements," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler.

"Our target market is health insurance plans and integrated healthcare delivery systems who want to do health risk assessments and preventative care management. WellChec™ is intended to be a one-stop shopping solution where these customers can get the information that they need without burdening the primary care doctors who are in short supply," continued Dr. Murphy-Chutorian.

About Semler Scientific, Inc.:

Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases. Semler's first patented and U.S. Food and Drug Administration cleared product, is FloChec®. FloChec® is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. Additional information about Semler can be found at

Forward-Looking Statements

This press release contains "forward-looking" statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words "may," "will," "expect," "anticipate," "estimate," "project," "would," "could" or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this release include statements regarding the ability of WellChec™ to be a one-stop shopping solution, provide enhanced revenue opportunity for Semler, provide greater return on investment for its clients, and ability of WellChec™ to reduce overall healthcare expenditures for disease management, among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific's actual results to differ materially from those discussed here, such as whether or not insurance plans and other customers will use the WellChec™ service, along with those detailed in Semler Scientific'sSEC filings, and involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date this release and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

To view the original version on PR Newswire, visit:

SOURCE Semler Scientific, Inc.

News Provided by Acquire Media

Contact Us

Semler Scientific, Inc.
2344 Walsh Avenue
Santa Clara, CA 95051